Maricopa Integrated Health Systems
Formulary Prior Auth Criteria

Drug: Strattera (atomoxetine HCL)

Therapy:
Is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)

Inclusions:
- Patient ≥ 6 years of age
- The patient has ADHD symptoms in more than one setting (e.g. school (work), home) and longer than six months
- Do the symptoms cause clinically significant impairment in social, academic or occupational functioning
- Has other primary psychiatric disorders and/or secondary environmental factors been considered
- Will the drug be used as an integral part of a total treatment program that may include psychological, educational, and social measures?
- Will the patient be monitored for adverse events, including weight loss and decreased growth velocity for children, and long-term usefulness
- Failure of formulary medications

Additional information:
Is a selective norepineprine reuptake inhibitor

Contraindications/Warnings/ Precautions:
- Hypersensitivity to any of the drug components
- Should not be taken with a MAOI, or within two weeks after discontinuing a MAOI. With other drugs that affect brain monoamine concentrations, there have been reports of serious, sometime fatal, reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma) when taken in combination with a MAOI. Some cases present with features resembling Neuroleptic malignant syndrome.
- Was associated with an increased risk of mydriasis and therefore its use is not recommended in patients with narrow angle glaucoma

Authorization:
Initially three months
Longer authorization of one year or to the end of the calendar year if Health Select

Medical Director_____
Date_____